je.st
news
Gilead's low-dose, high-impact HIV drug heads to the FDA
2015-04-08 05:46:56| Biotech - Topix.net
A next-generation HIV drug from Gilead Sciences Inc. , which could be more effective and have fewer side effects with a lower dosage, will go to federal regulators for a decision on whether it should be approved. The drug - a combination of Gilead's emtricitabine and tenofovir alafenamide, or TAF - is the second so-called F/TAF drug submitted by the Foster City-based company to the Food and Drug Administration.
Tags: drug
heads
hiv
fda
Category:Biotechnology and Pharmaceuticals